INTEGRA LIFESCIENCES HOLDINGS CORP

For the period ended Jun 30, 2024. Filed Jul 29, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Jul 29, 2024

IART$14.53+1.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 1. Financial Statements

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE INCOME

(Dollars in thousands, except per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2024	2023	2024	2023
Total revenue, net	$418,175	$381,267	$787,047	$762,113
Costs and expenses:
Cost of goods sold	192,258	174,241	354,296	322,216
Research and development	29,767	26,588	56,732	53,312
Selling, general and administrative	195,472	164,908	361,270	331,565
Intangible asset amortization	3,707	3,026	13,814	6,134
Total costs and expenses	421,204	368,763	786,112	713,227
Operating income	(3,029)	12,504	935	48,886
Interest income	5,058	3,939	10,098	8,046
Interest expense	(18,651)	(12,464)	(32,275)	(24,564)
Other (expense) income, net	1,437	(155)	827	1,234
(Loss) income before income taxes	(15,185)	3,824	(20,415)	33,602
(Benefit) provision for income taxes	(2,783)	(360)	(4,732)	5,192
Net (loss) income	$(12,402)	$4,184	$(15,683)	$28,410
Net (loss) income per share
Basic	$(0.16)	$0.05	$(0.20)	$0.35
Diluted	$(0.16)	$0.05	$(0.20)	$0.35
Weighted average common shares outstanding (See Note 13):
Basic	77,409	80,966	77,572	81,418
Diluted	77,409	81,151	77,572	81,739
Comprehensive income (See Note 14)	(20,482)	1,947	(19,303)	$22,975

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.